1.Treatment with Allogenic Mesenchymal Stromal Cells in a Murine Model of Systemic Lupus Erythematosus.
Chiara TANI ; Sabrina VAGNANI ; Linda CARLI ; Francesca QUERCI ; Anja A KÜHL ; Simone SPIECKERMANN ; Constanze Pamela CIELUCH ; Simone PACINI ; Rita FAZZI ; Marta MOSCA
International Journal of Stem Cells 2017;10(2):160-168
OBJECTIVE: Pre-clinical and uncontrolled studies in patients with systemic lupus erythematosus (SLE) showed that mesenchymal stromal cells (MSCs) have a potential therapeutic role in refractory cases. The optimal therapeutic strategy in these patients remain to be elucidated. Our aim was to test the hypothesis that repeated administrations of 1×10⁶/kg body weight of allogenic MSCs, that is a significantly lower dosage with respect to the fixed 1×10⁶ MSC used in animal models, can be effective in improving the clinical course of a murine SLE model. METHODS: Bone marrow derived MSCs were obtained from 12-week-old C57BL/6J mice. Seventy-five 8 weeks old female NZ mice were randomly assigned to receive via caudal vein the following alternative treatments: 1) single infusion of 10⁶ MSCs/kg body weight at 18 weeks of age (NZ(s18)) or at at 22 weeks of age (NZ(s22)); 2) multiple monthly infusions of 10⁶ MSCs/kg body weight starting at 18 weeks of age (NZ(M18)) or at 22 weeks of age (NZ(M22)); 3) saline infusions (NZ(c)) Fifteen 8 weeks old C57BL/6J mice (Envigo, Huntingdon, UK) were used as untreated controls (C). Weekly, body weight was recorded and twenty-four hour urines were collected by metabolic cages for each animal; proteinuria was detected by dipstick analysis. At sacrifice, peripheral blood samples were collected from mice and anti-dsDNA antibodies were detected by enzyme immunoassorbent assay (ELISA) method using commercial kits. At sacrifice, kidneys were analyzed for histopathology and immunohistochemical analysis for B220, CD4, MPO, CD4⁺Foxp3, F40/80 infiltration was performed. RESULTS: Proteinuria occurrence was delayed NZ(S) and NZ(M) mice, no differences were observed in anti-dsDNA autoantibody titer among the groups at the different time-points; at 36 weeks, no significant differences were observed in term of nephritis scores. Inflammatory cells deposition (MPO and F4/80 positive cells) in NZM was significantly higher than in NZ and NZ(S). An overexpression of B lymphocytes (B220) was found in NZ(M) while T regulatory cells (CD4⁺ Foxp3⁺ cells) were reduced in both NZ(S) and NZ(M) with respect to NZ(c). CONCLUSIONS: Overall, our study failed to show a positive effect of a treatment with murine MSCs in this model and, for some aspects, even deleterious results seem to be observed.
Animals
;
Antibodies
;
B-Lymphocytes
;
Body Weight
;
Bone Marrow
;
Female
;
Humans
;
Kidney
;
Lupus Erythematosus, Systemic*
;
Lupus Nephritis
;
Mesenchymal Stromal Cells*
;
Methods
;
Mice
;
Models, Animal
;
Nephritis
;
Proteinuria
;
Veins
2.A Biodegradable Polymeric Matrix for the Repair of Annulus Fibrosus Defects in Intervertebral Discs
Mohammad R. SAGHARI FARD ; Jan Philipp KRUEGER ; Stefan STICH ; Phil BERGER ; Anja A. KÜHL ; Michael SITTINGER ; Tony HARTWIG ; Michaela ENDRES
Tissue Engineering and Regenerative Medicine 2022;19(6):1311-1320
BACKGROUND:
Tissue defects in the annulus fibrosus (AF) due to intervertebral disc (IVD) degeneration or after nucleodiscectomy have little self-healing capacity. To prevent progressive degeneration of the IVD, the AF must be repaired. Biological closure has not yet been achieved and is a challenge for the research community. In this study, a scaffold made of absorbable poly (glycolic acid) (PGA) and hyaluronan (HA) that exhibit excellent biocompatibility and cell colonization properties was used to repair AF defects in an ovine model.
METHODS:
A partial resection was performed in AF in L3/4 or L4/5 of 10 sheep and PGA-HA scaffolds were implanted on the defects (n = 5), while defects in the control group were left untreated (n = 5). Three months post-operation, the lumbar discs were sectioned and stained with hematoxylin and eosin and safranin-O/fast-green. Histological features including proteoglycan content, annular structure, cellular morphology, blood vessel ingrowth and tear/cleft formation were scored using a modified scoring scheme by 3 investigators and evaluated by a pathologist independently.
RESULTS:
The treated AF exhibited significantly enhanced repair tissue structure with signs of proteoglycan formation compared to the untreated group. The median scores were 4.3 for the treated and 9.8 for the untreated group. Cystic degeneration, perivascular infiltration, inflammation and necrosis were only present in the untreated group. Blood vessel ingrowth and tear/cleft formation were increased, though not significant, in the untreated group while cell morphology was comparable in both groups.
CONCLUSION
PGA-HA scaffolds used for AF closure support repair tissue formation in an ovine lumbar disc defect model.